Navigation Links
Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
Date:5/17/2012

SUNNYVALE, Calif., May 17, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that clinical abstracts on Bruton's Tyrosine Kinase inhibitor, ibrutinib (formerly, PCI-32765) have been selected for oral presentations at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5, 2012 in Chicago, IL.

The update on data presented for the first time will specifically include: 1) safety and efficacy data from the phase II CLL single agent trial in treatment-naive patients; 2) safety and efficacy data from the phase Ib/II CLL combination trial with ofatumumab in relapsed or refractory patients and 3) safety and efficacy data from the phase Ib CLL combination trial with bendamustine and rituximab in relapsed or refractory patients. Pharmacyclics plans to present a material update on the ibrutinib clinical development program in a press release after the ASCO oral presentations on Monday, June 4, 2012 and expects to hold a conference call as well on Wednesday, June 6, 2012 at 1:30 PM PT/4:30 PM ET.

Oral Presentation at ASCO, Chicago, IL (June 1-5, 2012)
Date/Time: Monday, June 4, 2012; 10:15 AM — 10:30 AM (CT)
Location: E354a
Abstract # 6507: The Bruton's tyrosine kinase inhibitor PCI-32765 in treatment-naive chronic lymphocytic leukemia patients: Interim results of a phase Ib/II study. Dr. John C. Byrd et al., The Ohio State University, Columbus, Ohio.
This Abstract was selected to be presented at the "Best of ASCO Meetings."

Oral Presentation at ASCO, Chicago, IL (June 1-5, 2012)
Date/Time: Monday, June 4, 2012; 10:30 AM — 10:45 AM (CT)
Location: E354a
Abstract # 6508: A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pharmacyclics to Host a Conference Call on March 15, 2012 to Discuss Second Quarter Fiscal 2012 Financial and Operational Results
2. Pharmacyclics Inc. Receives Issue Notice of Significant Brutons Tyrosine Kinase (BTK) Patent
3. Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc.
4. Pharmacyclics Reports Fiscal 2012 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 53rd American Society of Hematology Annual Meeting
5. Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
6. Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
7. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
8. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
9. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
10. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
11. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Amgen (NASDAQ: ... Drug Administration (FDA) has granted priority review designation for ... Ivabradine is an oral drug that inhibits the ... sinoatrial node, the body,s cardiac pacemaker. 1 Ivabradine ... on myocardial contractility or ventricular repolarization. 1 Heart ...
(Date:8/27/2014)... -- "Fatty Liver Disease Global Clinical Trials Review, H2, ... trial scenario. This report provides elemental information and data ... Disease . It includes an overview of the trial ... of trial conduction across the globe. The databook offers ... phase, trial status, prominence of the sponsors and also ...
(Date:8/27/2014)... 2014 IRIDEX Corporation (NASDAQ: IRIX ) ... is scheduled to make an investor presentation at the ... Eastern Time on Wednesday, September 3, in New York City.  ... presentation will be available in the Investors section of the ... IRIDEX IRIDEX Corporation was founded in 1989 and ...
Breaking Medicine Technology:FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 2FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 4FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 5FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 6FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 7Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 2Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 3Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 4Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 5
... New Jersey, April 16, 2012 NoviPet , ... , will showcase new food supplements for dogs at the Backer,s ... take place on April 18-20 2012, in Atlantic City, New Jersey. ... company,s booth 834 at Atlantic City Convention Center. NoviPet intends to ...
... MUMBAI, India, April 15, 2012  Piramal Imaging SA ("Piramal"), ... PIRHEALTH, BSE: 500302], announced positive first results from a ... florbetaben reliably detects beta-Amyloid in the brain during life ... potential tool to aid in the diagnosis and assessment ...
Cached Medicine Technology:NoviPet to Present New Food Supplements for Dogs at Pet Industry Spring Trade Show 2Encouraging Phase III Study Results Show PET Imaging with Florbetaben Reliably Detects Beta-Amyloid in the Brain 2Encouraging Phase III Study Results Show PET Imaging with Florbetaben Reliably Detects Beta-Amyloid in the Brain 3
(Date:8/27/2014)... say knowledge is power, and a new UCLA study has ... men making the best decisions about how to treat their ... well educated about their disease have a much more difficult ... could negatively impact the quality of their care and their ... call for physicians, who can use the findings to target ...
(Date:8/27/2014)... Co-operative Research Centre into Microtechnologies, is coordinating ... innovative solutions based on microtechnologies to tackle ... life sciences, among others. IK4-Ikerlan, Ceit-IK4, IK4-Tekniker, ... with CIC microGUNE on this project, which ... Etortek 2013-2014 programme of the Government of ...
(Date:8/27/2014)... Men who eat over 10 portions a week of ... developing prostate cancer, new research suggests. , With 35,000 ... 10,000 deaths, prostate cancer is the second most common ... developed countries, which some experts believe is linked to ... following dietary and lifestyle recommendations reduces risk of prostate ...
(Date:8/27/2014)... German . There ... tumors. In case of pancreatic cancer, one of the most ... of the patients die within five years after the diagnosis. ... reduce this mortality rate. For preclinical and clinical tests of ... 5 million from investors. This will allow for the further ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Bedros Keuilian is ... in the world, the leading fitness boot camp marketing ... Gym Rescue reality series. One thing he knows very well ... a subject matter expert in the fitness business. , In ... he lays out a step-by-step instructional guide on how fitness ...
Breaking Medicine News(10 mins):Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 2Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 3Health News:Microtechnologies for driving forward mobility and human health 2Health News:Fighting prostate cancer with a tomato-rich diet 2Health News:Preclinical development of tumor therapeutic agent starts 2Health News:Bedros Keuilian Releases New Fitness Boot Camp Marketing Webinar on Building a Personal Brand 2Health News:Bedros Keuilian Releases New Fitness Boot Camp Marketing Webinar on Building a Personal Brand 3
... German . The human brain is the ... their corresponding projections, all woven together in a highly complex, ... practically insurmountable challenge to scientists. Now, however, a research team ... developed a method for tackling the mammoth task. Using two ...
... Alexandria, VA, USA The International and American Associations ... of Dental Research a study that investigated bone ... rare, primary malignant bone tumor that is more prevalent ... whether there is an association between fluoride and risk ...
... molecular medicine and genetics and of immunology and microbiology ... was awarded $1.7 million by the National Institute of ... Institutes of Health to explore how molecular elements in ... disease (NAFLD). The liver is an irreplaceable ...
... The Endocrine Society,s Journal of Clinical Endocrinology & Metabolism ... fructose corn syrup for two weeks as 25 percent of ... and triglycerides, which have been shown to be indicators of ... recommends that people consume only five percent of calories as ...
... This release is available in Spanish . ... finding breast tumors, and appears to increase a woman,s risk ... a large UC Davis study has found. The analysis ... most definitive findings to date on whether the popular mammography ...
... inherited mutations in a gene called HPRT1 lead to ... uncontrollable urges to bite their fingers, slam their arms ... mice with mutations in the same gene don,t behave ... of Medicine have identified a gene related to HPRT1, ...
Cached Medicine News:Health News:The brain's connectome -- from branch to branch 2Health News:The brain's connectome -- from branch to branch 3Health News:Study shows bone fluoride levels not associated with osteosarcoma 2Health News:NIH awards WSU researcher $1.7 million to study non-alcoholic fatty liver disease 2Health News:Fructose consumption increases risk factors for heart disease 2Health News:Popular mammography tool not effective for finding invasive breast cancer 2Health News:Gene gives clues to self-injurious behavior in rare disorder 2
... Size: 3.0 x 5.0 x 100 ... Sponge II line designed by Harvey ... is a closed cell sponge which ... soft with rounded edges to minimize ...
... Size: 2.3 x 6.4 x 80 ... Sponge II line designed by Harvey ... is a closed cell sponge which ... soft with rounded edges to minimize ...
... 5.5 x 7.5 x 80 mm. ... II line designed by Harvey A. ... a closed cell sponge which is ... with rounded edges to minimize scleral ...
... mm. Storz offers the original Scleral ... A. Lincoff, M.D. The material is ... non-toxic and non-antigenic. Implants are soft ... intrusion. These implants are packaged sterile ...
Medicine Products: